For Patients Full Prescribing Information With Medication Guide IFU Important Safety Information Contact a Representative

SUSTOL—the only 5-HT₃ RA with polymer technology that is engineered to last for ≥5 days*^1-7

Granisetron is a proven, effective treatment option for the prevention of CINV, and its therapeutic benefits are well established^1,2
The unique polymer technology of SUSTOL is engineered to allow for a sustained and controlled release of granisetron to prevent CINV for ≥5 days¹

Polymer technology enables a controlled release of granisetron

GRANISETRON/POLYMER COMBINATION

SUSTOL is engineered using a unique polymer technology that enables a controlled release of the otherwise shorter-acting granisetron^1,2

Polymer undergoes hydrolysis

RELEASE OF
GRANISETRON

After subcutaneous injection, the polymer undergoes hydrolysis and delivers granisetron in a controlled, sustained release for ≥5 days^1,2

Polymer hydrolyzes and is eliminated from the body

POLYMER
HYDROLYZES

After the granisetron has been released, the polymer hydrolyzes and is eliminated from the body^1,2

SUSTOL is indicated for the prevention of CINV due to MEC and AC combination chemotherapy.¹

5-HT₃ RA=5-hydroxytryptamine 3 receptor antagonist; AC=anthracycline/cyclophosphamide; CINV=chemotherapy-induced nausea and vomiting; MEC=moderately emetogenic chemotherapy; PK=pharmacokinetics.

The first 3-drug vs 3-drug trial (MAGIC)^8,9

Extended-release 5-HT₃ RA delivery with SUSTOL¹

See the PK data

$0 copay for eligible patients, broad support for your practice

Learn about Heron Connect^®

INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT₃ receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT₃ receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.

References:

SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2023.
Ottoboni, et al. J Exp Pharmacol. 2014.
Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., 2020.
Zofran [prescribing information]. GlaxoSmithKline, 2017.
Kytril [prescribing information]. Genentech, Inc., 2011.
Sancuso [prescribing information]. Kyowa Kirin, Inc., 2022.
Anzemet [prescribing information]. Validus Pharmaceuticals LLC, 2021.
Schnadig, et al. Future Oncol. 2016.
Zhou, et al. Ther Clin Risk Manag. 2015.